Claims for Patent: 7,691,983

Summary for Patent: 7,691,983

Title:	Chimera botulinum toxin type E
Abstract:	The present invention relates to a toxin comprising a modified light chain of a botulinum toxin type E, wherein the modified light chain comprises amino acid sequence PFVNKQFN (SEQ ID NO: 120) at the N-terminus, and amino acid sequence xExxxLL (SEQ ID NO: 112) at the C-terminus, wherein x is any amino acid.
Inventor(s):	Fernandez-Salas; Ester (Fullerton, CA), Steward; Lance E. (Irvine, CA), Herrington; Todd (Brookline, MA), Aoki; K. Roger (Coto de Caza, CA)
Assignee:	Allergan, Inc. (Irvine, CA)
Application Number:	11/036,532
Patent Claims:	1. A modified toxin comprising a modified light chain of a botulinum toxin type E, wherein the modification to the botulinum toxin type E light chain is the addition of one or more amino acid sequences comprising SEQ ID NO: 120 within the N-terminal 30 amino acids of a wild-type botulinum toxin type E light chain of SEQ ID NO: 136 and the addition of one or more leucine-based motifs of SEQ ID NO: 112 within the C-terminal 50 amino acids of a wild-type botulinum toxin type E light chain of SEQ ID NO: 136, wherein the addition of the amino acid sequence comprising SEQ ID NO: 120 increases biological half-life of the modified toxin relative to an identical modified toxin without the additional amino acid sequence comprising SEQ ID NO: 120, and wherein the addition of the leucine-based motif of SEQ ID NO: 112 increases biological half-life of the modified toxin relative to an identical modified toxin without the additional leucine-based motif comprising SEQ ID NO: 112. 2. The modified toxin of claim 1, wherein the addition of one or more amino acid sequences comprising SEQ ID NO: 120 is within the first 12 amino acids of the N-terminal of a wild-type botulinum toxin type E light chain of SEQ ID NO: 136, and the addition of one or more leucine-based motifs of SEQ ID NO: 112 is within the last 27 amino acids of the C-terminal of a wild-type botulinum toxin type E chain of SEQ ID NO: 136. 3. The modified toxin of claim 1, wherein the addition of one or more amino acid sequences comprising SEQ ID NO: 120 is within the first 8 amino acids of the N-terminal of a wild-type botulinum toxin type E light chain of SEQ ID NO: 136, and the addition of one or more leucine-based motifs of SEQ ID NO: 112 is within the last 23 amino acids of the C-terminal of a wild-type botulinum toxin type E light chain of SEQ ID NO: 136. 4. The modified toxin of claim 1, wherein the addition of one or more amino acid sequences comprising SEQ ID NO: 120 is within the first 8 amino acids of the N-terminal of a wild-type botulinum toxin type E light chain of SEQ ID NO: 136; and the addition of one or more leucine-based motifs of SEQ ID NO: 112 is prior to the last 16 amino acids at the C-terminal of a wild-type botulinum toxin type E light chain of SEQ ID NO: 136. 5. The modified toxin of claims 1, 2, 3, or 4, wherein the toxin further comprises a heavy chain of a Clostridial toxin. 6. The modified toxin of claim 5, wherein the heavy chain is a heavy chain of a botulinum toxin type A, botulinum toxin type B, botulinum toxin type C.sub.1, botulinum toxin type D, botulinum toxin type E, botulinum toxin type F, or botulinum toxin type G. 7. The modified toxin of claim 5, wherein the heavy chain is a heavy chain of a botulinum toxin type E. 8. The toxin of claim 5, wherein the heavy chain is a heavy chain of a botulinum toxin type A. 9. The modified toxin of claim 1, wherein the leucine-based motif added is SEQ ID NO: 1, SEQ ID NO: 4, SEQ ID NO: 6, or SEQ ID NO: 13. 10. The modified toxin of claim 1, wherein the modified botulinum toxin type E light chain is SEQ ID NO: 126. 11. The modified toxin of claim 1, wherein the modified botulinum toxin type E light chain is SEQ ID NO: 131. 12. A modified toxin comprising a modified light chain of SEQ ID NO: 136, wherein one or more of SEQ ID NO: 120 occur within the N-terminal 30 amino acids of the light chain, and one or more of SEQ ID NO: 112 occur within the C-terminal 50 amino acids of the light chain wherein the addition of one or more SEQ ID NO: 120 increases biological half-life of the modified toxin relative to an identical modified toxin without the addition of one or more SEQ ID NO: 120, and wherein the addition of one or more SEQ ID NO: 112 increases biological half-life of the modified toxin relative to an identical modified toxin without the addition of one or more SEQ ID NO: 112.

Details for Patent 7,691,983

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Solstice Neurosciences, Llc	MYOBLOC	rimabotulinumtoxinb	Injection	103846	12/08/2000		2020-07-21